View Older Stories View More Recent Stories

May 9, 2024 04:01PM Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024 08:00AM OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
May 2, 2024 08:00AM Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Apr 30, 2024 08:03AM Lineage Cell Therapeutics (LCTX) Receives Grant From California Institute for Regenerative Medicine
Apr 30, 2024 08:00AM Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
Apr 29, 2024 04:31PM Lineage Cell Therapeutics (LCTX) Announces Board Changes
Apr 29, 2024 04:30PM Lineage Announces Changes to Board of Directors
Apr 1, 2024 08:00AM Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
Mar 18, 2024 08:00AM Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
Mar 13, 2024 08:00AM RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Mar 11, 2024 08:00AM RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
Mar 7, 2024 04:01PM Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 29, 2024 08:00AM Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
Feb 13, 2024 08:01AM Lineage (LCTX) Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Feb 13, 2024 08:00AM Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Feb 9, 2024 09:15AM Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
Feb 6, 2024 09:15AM Lineage Cell Therapeutics (LCTX) Prices 13.46M Share Offering at $1.04/sh
Feb 6, 2024 09:15AM Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
Jan 16, 2024 08:00AM RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
Dec 18, 2023 08:05AM Lineage Cell Therapeutics (LCTX) Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Dec 18, 2023 08:00AM Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Nov 9, 2023 04:01PM Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 1, 2023 08:00AM Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
Oct 24, 2023 08:00AM RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
Oct 11, 2023 08:04AM Lineage Cell Therapeutics (LCTX) Granted US Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
Oct 11, 2023 08:00AM Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
Oct 5, 2023 08:00AM Lineage Cell Therapeutics (LCTX) Reports RG6501 Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure
Oct 5, 2023 08:00AM RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sep 19, 2023 08:00AM Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
Sep 13, 2023 08:00AM RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
Sep 11, 2023 08:00AM Lineage to Present at 2023 International Spinal Research Trust Network Meeting
Sep 6, 2023 08:00AM Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
Aug 29, 2023 08:00AM Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
Aug 10, 2023 04:01PM Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 3, 2023 08:00AM Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Jul 24, 2023 08:03AM Lineage Cell Therapeutics (LCTX) and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
Jul 24, 2023 08:00AM Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
May 22, 2023 08:00AM Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
May 11, 2023 04:01PM Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 9, 2023 08:00AM Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
May 4, 2023 08:00AM Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Apr 26, 2023 08:03AM Lineage Cell Therapeutics (LCTX) Announces RG6501 Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to AMD
Apr 26, 2023 08:00AM RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Apr 18, 2023 08:00AM Lineage to Present at 2023 AAPS National Biotechnology Conference
Mar 30, 2023 08:00AM Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
Mar 20, 2023 08:00AM RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
Mar 9, 2023 04:01PM Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Mar 6, 2023 08:00AM RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
Mar 2, 2023 08:00AM Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
Feb 22, 2023 08:07AM Lineage Cell Therapeutics (LCTX) Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
View More Recent Stories View Older Stories